CVRX
CVRx, Inc.
CVRX trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over CVRX overall, supported by stronger fundamentals and stronger valuation.
CVRX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
CVRX's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CVRX PE Valuation
CVRX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CVRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect CVRX's earnings, revenue and profitability to hold roughly steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over CVRX on the outlook, with more favorable earnings and revenue expectations.
CVRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.00 | -$0.02 |
| Q2 2026 | -$1.97 | +$0.09 |
| Q1 2026 | -$2.01 | +$0.13 |
| Q4 2025 | -$2.04 | +$0.61 |
| Q3 2025 | -$1.98 | +$0.73 |
| Q2 2025 | -$2.06 | +$0.51 |
| Q1 2025 | -$2.14 | +$0.34 |
| Q4 2024 | -$2.65 | -$0.66 |
CVRX is still losing money, but less than at its worst: $2.00 per share over the past year, against $2.71 at its worst in late 2024.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CVRX on earnings quality, reporting a profit while its opponent remains loss making.
CVRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13.8M | -5.8% |
| Q2 2026 | $15.7M | +16% |
| Q1 2026 | $14.8M | +20% |
| Q4 2025 | $16M | +4.4% |
| Q3 2025 | $14.7M | +9.8% |
| Q2 2025 | $13.6M | +15% |
| Q1 2025 | $12.3M | +15% |
| Q4 2024 | $15.3M | +36% |
CVRX's revenue is growing: $14M last quarter, down 5.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -94% | -11 points |
| Q2 2026 | -83% | +23 points |
| Q1 2026 | -82% | +27 points |
| Q4 2025 | -70% | -2.8 points |
| Q3 2025 | -84% | +14 points |
| Q2 2025 | -106% | +13 points |
| Q1 2025 | -109% | +98 points |
| Q4 2024 | -67% | +19 points |
CVRX's operating margin was −94% last quarter, down 11 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CVRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CVRX on profitability, with a higher operating margin.
CVRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$11M | -$991K |
| Q2 2026 | -$8.9M | -$899K |
| Q1 2026 | -$12.3M | +$595K |
| Q4 2025 | -$9.8M | -$1.8M |
| Q3 2025 | -$10M | +$443K |
| Q2 2025 | -$8M | +$2.1M |
| Q1 2025 | -$12.9M | -$1.1M |
| Q4 2024 | -$8.1M | -$52K |
CVRX has burned cash in almost every quarter: −$42M over the past year, against −$39M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CVRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CVRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +731K shares |
| 1 year | +4.1% | +1.1M shares |
| 3 years | +31% | +6.4M shares |
| 5 years | +7343% | +26.9M shares |
CVRX has 27M diluted shares, up 4.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CVRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CVRX Net Leverage
CVRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CVRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.1 | Oversold |
| Stochastic | 1.7 | Oversold |
CVRX's weekly RSI is 26 (oversold) and its Stochastic is 2 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CVRX PE vs Healthcare Sector
CVRX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CVRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.43 | 56% below |
| 20 week MA | $2.88 | 78% below |
| 50 week MA | $5.38 | 88% below |
| 100 week MA | $7.50 | 92% below |
| 200 week MA | $11.1 | 94% below |
CVRX is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CVRX on trend strength, trading above more of its moving averages.
CVRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.5 | $12.2 | -52% |
| 2022 | $12.2 | $16.7 | +37% |
| 2023 | $16.7 | $31.4 | +88% |
| 2024 | $31.4 | $13.2 | -58% |
| 2025 | $13.2 | $7.42 | -44% |
| 2026 YTD | $7.42 | $0.63 | -92% |
CVRX has finished lower in three of the last five years. It's down 92% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CVRX on returns for 2026, with the stronger performance.